Wong-Pan covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Resmed, and Fisher & Paykel Healthcare Corporation Limited. According to TipRanks, Wong-Pan has an average return of -2.9% and a 44.63% success rate on recommended stocks.
Currently, the analyst consensus on Monash IVF Group Ltd is a Moderate Buy with an average price target of A$0.82, which is a 22.39% upside from current levels. In a report released on June 3, Bell Potter also maintained a Hold rating on the stock with a A$0.77 price target.
Based on Monash IVF Group Ltd’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of A$137.86 million and a net profit of A$7.16 million. In comparison, last year the company earned a revenue of A$140.39 million and had a net profit of A$17.01 million
